Pooled Analysis of Mesenchymal Stromal Cell-Derived Extracellular Vesicle Therapy for Liver Disease in Preclinical Models

Fang, Xinru; Gao, Feiqiong; Yao, Qigu; Xu, Haoying; Yu, Jiong; Cao, Hong; Li, Shibo

doi:10.3390/jpm13030441

Cited by 3 publications

(1 citation statement)

References 76 publications

(203 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 141 Exosomes derived from various MSCs have been used recently by researchers to treat various liver failure models, proving that they can protect against liver damage. 142 Yan et al 143 administered human umbilical cord MSC-derived exosomes (ucMSC-Ex) at low (8 mg/kg), medium (16 mg/kg), and high (32 mg/kg) doses to mice with carbon tetrachloride (CCl 4 )-induced liver failure. Large areas of steatosis and hepatocellular necrosis were found in the liver tissues of mice administered the low dose, whereas the liver tissue lesions in mice in the medium- and high-dose groups were significantly alleviated.…”

Section: Msc-evs and Acute Liver Injurymentioning

confidence: 99%

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

Zhu,

Wang,

Guo

et al. 2024

JIR

View full text Add to dashboard Cite

Chronic liver conditions are associated with high mortality rates and have a large adverse effect on human well-being as well as a significant financial burden. Currently, the only effective treatment available for the effects of liver failure and cirrhosis resulting from the progression of several chronic liver diseases is liver transplantation carried out at the original location. This implies that developing novel and effective treatments is imperative. Regenerative medicine has long been associated with stem cell therapy. Mesenchymal stem cells (MSCs), a type of cell with great differentiation potential, have become the preferred source for stem cell therapy. According to recent studies, MSCs’ paracrine products—rather than their capacity for differentiation—play a significant therapeutic effect. MSC exosomes, a type of extracellular vesicle (MSC-EV), came into view as the paracrine substances of MSCs. According to research, MSC exosomes can maintain tissue homeostasis, which is necessary for healthy tissue function. All tissues contain them, and they take part in a variety of biological activities that support cellular activity and tissue regeneration in order to preserve tissue homeostasis. The outcomes support the use of MSCs and the exosomes they produce as a therapeutic option for a range of diseases. This review provides a brief overview of the source of MSC-EVs and outlines their physiological roles and biochemical capabilities. The elucidation of the role of MSC-EVs in the recovery and repair of hepatic tissues, as well as their contribution to maintaining tissue homeostasis, is discussed in relation to different chronic liver diseases. This review aims to provide new insights into the unique roles that MSC-EVs play in the treatment of chronic liver diseases.

show abstract

Section: Msc-evs and Acute Liver Injurymentioning

confidence: 99%

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

Zhu,

Wang,

Guo

et al. 2024

JIR

View full text Add to dashboard Cite

show abstract

The efficacy of extracellular vesicles for acute lung injury in preclinical animal models: a meta-analysis

Zhang,

Cheng,

Zeng

et al. 2024

BMC Pulm Med

View full text Add to dashboard Cite

Background With the increasing research on extracellular vesicles (EVs), EVs have received widespread attention as biodiagnostic markers and therapeutic agents for a variety of diseases. Stem cell-derived EVs have also been recognized as a new viable therapy for acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). To assess their efficacy, we conducted a meta-analysis of existing preclinical experimental animal models of EVs for ALI treatment. Methods The database was systematically interrogated for pertinent data encompassing the period from January 2010 to April 2022 concerning interventions involving extracellular vesicles (EVs) in animal models of acute lung injury (ALI). The lung injury score was selected as the primary outcome measure for statistical analysis. Meta-analyses were executed utilizing RevMan 5.3 and State15.1 software tools. Results The meta-analyses comprised 31 studies, exclusively involving animal models of acute lung injury (ALI), categorized into two cohorts based on the presence or absence of extracellular vesicle (EV) intervention. The statistical outcomes from these two study groups revealed a significant reduction in lung injury scores with the administration of stem and progenitor cell-derived EVs (SMD = -3.63, 95% CI [-4.97, -2.30], P < 0.05). Conversely, non-stem cell-derived EVs were associated with an elevation in lung injury scores (SMD = -4.34, 95% CI [3.04, 5.63], P < 0.05). EVs originating from stem and progenitor cells demonstrated mitigating effects on alveolar neutrophil infiltration, white blood cell counts, total cell counts in bronchoalveolar lavage fluid (BALF), lung wet-to-dry weight ratios (W/D), and total protein in BALF. Furthermore, pro-inflammatory mediators exhibited down-regulation, while anti-inflammatory mediators demonstrated up-regulation. Conversely, non-stem cell-derived EVs exacerbated lung injury. Conclusion In preclinical animal models of acute lung injury (ALI), the administration of extracellular vesicles (EVs) originating from stem and progenitor cells demonstrably enhances pulmonary function. This ameliorative effect is attributed to the mitigation of pulmonary vascular permeability and the modulation of immune homeostasis, collectively impeding the progression of inflammation. In stark contrast, the utilization of EVs derived from non-stem progenitor cells exacerbates the extent of lung injury. These findings substantiate the potential utility of EVs as a novel therapeutic avenue for addressing acute lung injury.

show abstract

The function and effectiveness of MSCs in preclinical models of diseases

Xie,

Zhou,

et al. 2024

Stem Cell Transplantation [Working Title]

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) have shown immense promise across diverse fields, particularly in treating various diseases. A multitude of preclinical investigations, encompassing both laboratory cellular-level studies and animal trials, have demonstrated the significant effectiveness of MSCs in addressing a broad spectrum of diseases. These studies collectively highlight the enormous potential of therapies utilizing MSCs across a range of medical scenarios. From neurological and cardiovascular disorders to autoimmune and musculoskeletal disorders, including recent challenges like COVID-19, MSCs present therapeutic possibilities due to their versatile capabilities. These discoveries lay a robust foundation for further clinical research and the eventual translation of MSC-based treatments into mainstream clinical practice, offering renewed optimism for patients contending with complex medical conditions.

show abstract

Pooled Analysis of Mesenchymal Stromal Cell-Derived Extracellular Vesicle Therapy for Liver Disease in Preclinical Models

Cited by 3 publications

References 76 publications

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

Mesenchymal Stem Cell–Derived Exosomes in Various Chronic Liver Diseases: Hype or Hope?

The efficacy of extracellular vesicles for acute lung injury in preclinical animal models: a meta-analysis

The function and effectiveness of MSCs in preclinical models of diseases

Contact Info

Product

Resources

About